Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Tocris Bioscience™ Carfilzomib
GREENER_CHOICE

Catalog No. 718810
Change view
Click to view available options
Quantity:
10 mg
50 mg
2 product options available for selection
Product selection table with 2 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
71-881-0 10 mg
71-885-0 50 mg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 2 options available.
2 options
This item is not returnable. View return policy
Catalog No. 71-881-0 Supplier Tocris Bioscience™ Supplier No. 7188/10
Only null left
Add to Cart
Add to Cart
This item is not returnable. View return policy

Potent irreversible proteasome inhibitor; active in vivo

Carfilzomib is a potent irreversible proteasome inhibitor. Preferentially inhibits the chymotrypsin-like β5 subunit of the constitutive 20S proteasome (IC50 = 5.2 nM) and the β5i subunit of the immunoproteasome 20Si (LMP7; IC50 = 14 nM) in vitro with minimal cross-reactivity to other proteases. Exhibits little or no effect on PGPH and T-L activities. Activates prosurvival autophagy and induces cell apoptosis. Acts synergistically with dexamethasone (Cat. No. 1126). Suppresses tumor growth in an in vivo xenograft model. Decreases bone resorption and enhances bone formation in non-tumor bearing mice.

Specifications

Chemical Name or Material (αS)-α-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1 S)-3-methyl-1-[[(2 R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide
CAS 868540-17-4
Quantity 10 mg
Target Proteasome Inhibitors
Molecular Formula C40H57N5O7
Purity 0.98
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.